Emerald Health Therapeutics Launches Island Mist, One of Canada’s Highest CBD and CBD to THC Ratio Dried Flower Products
18 September 2017 - 9:00PM
Emerald Health Therapeutics Inc. (Therapeutics) (TSX-V:EMH)
(OCTQX:EMHTF) has released Island Mist, its proprietary high
cannabidiol (CBD) and high CBD to THC ratio dried flower product.
This Indica-dominant strain, which came out of Emerald’s broad seed
bank through extensive screening and characterization,
contains 15.9% CBD and just 0.4% THC, a ratio of 40:1. This product
can be purchased by holders of a medical license registered with
Emerald Health Botanicals (Botanicals), Therapeutics’ wholly owned
subsidiary and a Licensed Producer under Access to Cannabis for
Medical Purposes Regulations (ACMPR).
Botanicals currently sells a line of six dried
flower products, including four strains with THC levels ranging
from 16.3% to 21.5%; a high CBD strain; and a strain containing
both THC and CBD.
Botanicals now offers eight oils with varying
levels of THC, THCA, CBD, and THC to CBD ratios. This product line
includes the company’s recently launched CBD-25 and CBD-50 medical
cannabis oils containing approximately 25 milligrams and 50 mg of
CBD per milliliter. Management believes CBD-50 contains the highest
amount of CBD per milliliter on the ACMPR market today. CBD-50
provides a unique option to doctors and patients seeking high CBD
potency with minimal THC."Island Mist offers patients who prefer
dried flower with significant CBD and minute amounts of THC and
thus little to no psychoactive effects," said Dr. Bin Huang,
President and CEO of Emerald. "We have built a balanced product
line that we will add to with our continuing pursuit of distinct
products to meet different needs and expectations in the ACMPR
marketplace and the anticipated legal Canadian recreational market
in 2018.”Join us on our journey of making lives better
through cannabis science.
About Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. (TSXV: EMH;
OTCQX: EMHTF) operates primarily through Emerald Health Botanicals
Inc. ("Botanicals"), a wholly owned subsidiary of the Company and a
Licensed Producer under the Access to Cannabis for Medical Purposes
Regulations. Botanicals is authorized to produce and sell both
dried medical cannabis flower and medical cannabis oil in Canada.
Botanicals currently operates an indoor facility in Victoria, BC,
and is progressing on expansion plans for a 32-acre property in
Metro Vancouver and a joint venture with Village Farms utilizing a
25 acre existing greenhouse complex in Delta, BC. Botanicals is one
of Canada's most medically focused licensed producers, with a team
highly experienced in life sciences product development and
large-scale agribusiness. Its vision is to be a leading provider of
cannabis products through its production capabilities, proprietary
genetics, value-added products and branding, and superb customer
experience. Emerald Health Therapeutics is part of the Emerald
Health group, which comprises multiple companies advancing diverse
botanical, nutraceutical and pharmaceutical products that may
provide wellness and medical benefits by interacting with the
body’s endocannabinoid system.
For investor and media contacts:
invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Statements Regarding Forward
Looking Information
Certain statements in this press release
constitute forward-looking statements, within the meaning of
applicable securities laws. All statements that are not
historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, are "forward-looking statements".
We caution you that such "forward-looking
statements" involve known and unknown risks and uncertainties that
could cause actual and future events to differ materially from
those anticipated in such statements.
Forward-looking statements include, but are not
limited to, statements with respect to legalization of
non-therapeutic cannabis sales in Canada; participation in the
legalized non-therapeutic cannabis industry; growth in the
extract-based market; increased production of cannabis; commercial
operations; construction or conversion of production facilities;
applications for licensing; obtaining such licenses; commencement
of production of cannabis at the Company’s facilities; estimates of
production capacity at such facilities; contributions of cash to
the JV; international opportunities for the Company; commencement
of clinical trials; the Company becoming a leading Canadian
supplier of cannabis products; expected timing of any of the above
matters; and other information that is based on forecasts of future
results, estimates of amounts not yet determinable and assumptions
of management.
Emerald Health Therapeutics Inc. does not
intend, and does not assume any obligation, to update these
forward-looking statements except as required by law. These
forward-looking statements involve risks and uncertainties relating
to, among other things, failure of the federal government to
approve legislation legalizing sales of non-therapeutic adult-use
cannabis; failure to obtain Health Canada and other regulatory
approvals; failure to obtain necessary financing; results of
production and sale activities; the Company's historical experience
with medical marijuana operations; results of scientific research;
uninsured risks; regulatory changes; difficulties in construction
or in obtaining qualified contractors to complete construction or
conversion of facilities; availability of production facilities;
timeliness of government approvals and the granting of permits and
licenses; changes in prices and costs; actual operating and
financial performance of facilities; equipment and processes
relative to specifications and expectations; as well as the other
risk factors set out in the Company’s annual information form and
other filing with the applicable Canadian securities regulators,
which may be viewed at www.sedar.com. Actual results may differ
materially from those expressed or implied by such forward-looking
statements.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Apr 2024 to May 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From May 2023 to May 2024